---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-007715"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T02:58:01.124430+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vistagen Q3 FY2026 net loss $18.9M; PALISADE-4 topline expected H1 2026

## Summary
- Net loss $18.9M for quarter ended Dec 31, 2025, vs $14.1M a year ago; R&D expense $14.2M, G&A $5.6M.
- Cash and equivalents $61.8M as of Dec 31, 2025; company targeting disciplined capital allocation.
- PALISADE-4 Phase 3 trial of fasedienol for social anxiety ongoing; topline results from randomized portion expected H1 2026.
- Previous PALISADE-3 Phase 3 missed primary endpoint in Dec 2025; safety data favorable.
- Appointed Nick Tressler as CFO in Dec 2025; refisolone IND submission for hot flashes planned H1 2026.

## SEC filing metadata
- accession: 0001628280-26-007715
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000162828026007715/0001628280-26-007715-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000162828026007715/vtgn-20260212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-007715
- JSON: https://secwatch.observer/filing/0001628280-26-007715.json
- Plain text: https://secwatch.observer/filing/0001628280-26-007715.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.